We are open to work under different business models including:
- In-licensing
- Co-marketing
- Co-promotion
- Distribution
- Local representation of international companies
Some of our collaborations include
| COMPANY |
COUNTRY |
SINCE |
PRODUCT (API) |
| Italfarmaco |
IT |
1990 |
Legofer® (iron proteinsuccinylate) |
| Bayer |
DE |
2012 |
Xarelto® (rivaroxaban) |
| Infectopharm |
DE |
2016 |
Fomicyt® (fosfomycin sodium) |
| Takeda Pharma |
CH |
2015
2015
2015 |
Vipidia® (alogliptin)
Vipdomet® (alogliptin + metformin)
Incresync® (alogliptin + pioglitazone) |
| Servier |
FR |
2018 |
Prestalia® (perindopril + amlodipine) |
| Bionorica |
DE |
2022
2022
2022 |
Sinupret® extract (Gentiana lutea L., Primula veris L., Rumex crispus L., Sambucus nigra L., Verbena officinalis L.)
Canephron® Uno (Centaurium erythraea Rafn s.l., herba, Levisticum officinale Koch., radix, Rosmarinus officinalis L., folium)
Imupret® (Althaeae radix, Quercus cortex, Matricariae flos, Taraxaci herba, Equiseti herba, Millefolii herba, Juglandis folium) |
| Axunio Pharma GmbH |
DE |
2023 |
Pirfenidone Axunio® (pirfenidone) |
ELPEN is always seeking for on/off patent originator or biosimilar products, for which Phase III clinical trials have been completed, and for which FDA or EMA marketing authorization procedures have started or will be starting shortly. We may also assess potential partnerships involving products already authorized and marketed in the Greek market, and last but not least we seek to work with companies that are not currently represented in Greece.
At present ELPEN's portfolio in its domestic markets includes Rx and OTC products from therapeutic areas such as:
- Respiratory
- Cardiovascular
- Central Nervous System
- Infections
- Metabolic
- Gastrointestinal
- Musculoskeletal
- HIV
- Urology
- Pediatrics
- Women Healthcare
To find out more, please contact us at bdgen@elpen.gr